BioCentury
ARTICLE | Product Development

Survey says: Companies seek regulatory flexibility as COVID-19 makes clinical disruptions the new norm

A BioCentury/BIO joint survey finds COVID-19 has forced many companies to modify their clinical trials

March 26, 2020 1:57 AM UTC


Access this Article